Zacks Company Profile for Bio-Techne Corp (TECH : NSDQ) |
|
|
|
Company Description |
Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota.
Number of Employees: 3,100 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $51.26 |
Daily Weekly Monthly
 |
20 Day Moving Average: 1,941,941 shares |
Shares Outstanding: 156.77 (millions) |
Market Capitalization: $8,035.88 (millions) |
Beta: 1.47 |
52 Week High: $80.95 |
52 Week Low: $46.01 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-4.61% |
-6.29% |
12 Week |
2.25% |
-7.12% |
Year To Date |
-28.84% |
-34.04% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Kim Kelderman - President; Chief Executive Officer and Director
Robert V. Baumgartner - Chairman of the Board and Director
James Hippel - Chief Financial Officer
Julie Bushman - Director
Rupert Vessey - Director
|
|
Peer Information
Bio-Techne Corp (CORR.)
Bio-Techne Corp (RSPI)
Bio-Techne Corp (CGXP)
Bio-Techne Corp (BGEN)
Bio-Techne Corp (GTBP)
Bio-Techne Corp (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09073M104
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 10/29/25
|
|
Share - Related Items
Shares Outstanding: 156.77
Most Recent Split Date: 11.00 (4.00:1)
Beta: 1.47
Market Capitalization: $8,035.88 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.62% |
Current Fiscal Quarter EPS Consensus Estimate: $0.37 |
Indicated Annual Dividend: $0.32 |
Current Fiscal Year EPS Consensus Estimate: $1.76 |
Payout Ratio: 0.18 |
Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: -0.02 |
Estmated Long-Term EPS Growth Rate: 8.90% |
Last Dividend Paid: 08/18/2025 - $0.08 |
Next EPS Report Date: 10/29/25 |
|
|
|
|